Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘EORTC-NCI-AACR Molecular Targets’

Gaudi Cathedral, Barcelona

It seems oddly surreal of my photo editor to remind me that on this day in the past we were in Barcelona (right) for some conference or other and this year’s EORTC-NCI-AACR Molecular Targets meeting (aka the Triple in industry parlance) was cancelled in Spain in favour of a virtual meeting, thanks to the ongoing pandemic.

There is no doubt that thinking big in cancer research is vitally important, but sometimes we have to consider the difference between building cathedrals for the long-term rather than building simple walls as short-term fixes.

Here we consider some examples in the context of oncology drug development and also open the monthly October BSB mailbag…

To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the EORTC-NCI-AACR Triple meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

What’s the elephant in the KRASi room?

It’s time to look at the latest update on KRAS mutation specific agents in clinical development as we turn the spotlight from the Amgen sotorasib data at ESMO to Mirati’s G12C selective agent, MRTX849, now known as adagrasib.

At the Targets meeting last year in Boston, Dr Pasi Jänne presented the initial findings from phase 1/1b the lung cancer cohort.  This time around we get to hear him provide an update on the combined phase 1/1b plus phase 2 results, plus there’s an additional presentation from Dr Melissa Johnson on the non-lung cancer cohort i.e. GI and other cancers.

Ahead of the presentation this morning (US east coast time), BSB caught up with Dr Jänne for his perspectives on the progress made and where things are headed in the near-term.  He offers a thoughtful and candid approach to tackling a hard to treat cancer subset with targeted therapy.

To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the EORTC-NCI-AACR Triple meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

We have two stories to share today from the EORTC-NCI-AACR Molecular Targets conference, which are posted separately owing to different embargo times.

The second posting later focuses exclusively on KRAS and Mirati’s turn in the spotlight.

Due to the embargo, it will not be available until 1545 hrs CET (1045 hrs ET) and will include some thought leader perspectives on the data.  I’ll add the link here in due course.

Developmental Therapeutics is often a cases of sunny days or stormy waters ahead…

Meanwhile, in the first post (below) we take a keen look at some of the new developmental therapeutics approaches coming through company pipelines.

Which ones shine might brightly and which ones lose their lustre?

As is often the case with early stage trials, translating rational science in preclinical setting doesn’t always translate well into the clinic when humans receive a therapy or particular combination of agents.

To this end, you might be surprised at how much PK/PD issues, half life, dosing/scheduling and other many other factors can severely impact the therapeutic window.

In this post, we look carefully at several targets we have been following preclinically for a while and finally initial clinical is either available or they are heading into the clinic – what can we learn from the presentations?

To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the EORTC-NCI-AACR Triple meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Munich – the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics conference is one of my favourite meetings on the cancer circuit. It’s small enough that you can catch people in the corridor and have a quick chat, while at the same time large enough that it attracts quality data. It’s also the place where you find people who think outside the box.

I want to hear from thought leaders who have the potential to be disrupters.

feuerwurstTalking of another kind of disruption, sadly the travel chaos caused by the Lufthansa pilot’s strike(s) meant some people didn’t make it to the meeting or arrived late. Despite the best efforts of Lufthansa, there was still a good turnout of posters today and several caught my attention!

Those who follow our cancer conference coverage know that the poster hall is often where the gems and insights are to be found, particularly when it comes to early drug development.

If you couldn’t make it to Munich, this post has commentary on four gems from the Wednesday poster session at EORTC-NCI-AACR that caught my attention. I’ve chosen to focus on novel targets and novel combination approaches…

Subscribers can login to read more or you can purchase access.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!